Puribel

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Puribel

Property Description
Active Ingredient Allopurinol
Form Oral tablets (primary)
Pharmacological Class Xanthine Oxidase Inhibitor (XOI)
General Purpose To lower and control uric acid levels
Origin Synthetic Compound (Purine Analog)

What Type of Medicine is Puribel (Allopurinol)?

Puribel is a prescription-only medication with the active ingredient Allopurinol, classifying it as a synthetic compound and a single-ingredient product. Allopurinol is chemically defined as a purine analog, meaning its structure mimics natural purine bases found in the body, which enables its specific interaction with metabolic enzymes. Puribel is primarily supplied as tablets intended for oral administration, the standard form for chronic therapy, although an intravenous powder for injection preparation is also recognized for patients unable to take the medicine by mouth. Allopurinol is the substance used in widely recognized generic and brand-name formulations, placing Puribel within a long-established therapeutic family.


Pharmacological Class: What is a Xanthine Oxidase Inhibitor?

Puribel belongs to the pharmacological class known as a Xanthine Oxidase Inhibitor (XOI). This classification signifies the medication's function: it specifically blocks the activity of the enzyme xanthine oxidase (XO), a key enzyme in the final steps of purine catabolism. The active substance, Allopurinol, is a foundational inhibitor utilized in the chronic treatment of excess urate production. The conclusion is that this medicine helps by directly blocking the body's natural process for making uric acid. This mechanism is clinically recognized for providing long-term stabilization of urate levels, a key differentiator from medications that only manage acute symptoms.


What is the General Purpose of Puribel’s Action?

The general purpose of Puribel is to provide hypouricemic action, which is the consistent, therapeutic reduction of uric acid production in the body. By inhibiting the XO enzyme, the medication effectively manages the underlying issue of hyperuricemia (excessive blood uric acid levels). Allopurinol is a foundational therapy for the chronic management of this metabolic state. This confirms the drug's essential role in keeping the amount of uric acid in the blood at a healthy level. This controlled lowering of the uric acid load is the general therapeutic objective, helping to prevent the saturation of the blood that leads to the accumulation of monosodium urate crystals in tissues, a typical scenario in patients with recurring high urate counts.

What side effects are possible with Puribel?

Possible Side Effects and Safety Information for Puribel

Puribel (active ingredient: febuxostat) carries a Boxed Warning from regulatory authorities regarding an increased risk of heart-related death and death from all causes compared to the gout medicine allopurinol. This risk was observed in a large post-market safety clinical trial involving patients with gout who had established cardiovascular disease.

Safety Restrictions and Limitations

Due to the documented cardiovascular risk, Puribel is generally reserved for use only in adult patients with gout who have had an inadequate response to a maximally tolerated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is otherwise not advisable. It is not recommended for the treatment of asymptomatic hyperuricemia.

Serious Adverse Reactions

The following serious and clinically significant adverse reactions have been reported in regulatory documents:

  • Cardiovascular Death: Increased risk observed, including sudden cardiac death.
  • Hepatic Effects: Cases of hepatic failure, some fatal, have been reported. Patients must be monitored for signs of liver injury.
  • Serious Skin Reactions: Reactions include Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and Toxic Epidermal Necrolysis. Treatment should be discontinued if a serious skin reaction is suspected.

Common Adverse Reactions

Adverse reactions reported in 1% of patients in clinical trials include liver function abnormalities, nausea, arthralgia (joint pain), and rash. An increase in gout flares is frequently observed upon starting treatment due to the change in serum uric acid levels; prophylaxis is often recommended during this initial period.

Overdose and Emergency Response

The regulatory overdose profile for Puribel addresses the risks of severe systemic toxicity and metabolic complications. Acute high-dose exposure may initially present with nonspecific gastrointestinal symptoms, including nausea, vomiting, or diarrhea. However, the primary concern documented by authorities is the development of life-threatening severe cutaneous reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as irreversible organ damage.

Worsened renal function, hepatic necrosis, and generalized vasculitis are severe outcomes of systemic toxicity cited in official labeling. A key metabolic complication of high exposure is the potential for xanthine crystalluria (xanthine stone formation) in the urinary tract.

Immediate medical attention is explicitly required at the first appearance of a skin rash or other signs of sensitivity, as this may be the initial indication of a rapidly progressing, sometimes fatal, reaction. There is no specific antidote listed for a Puribel overdose. Management procedures described are supportive, including maintaining adequate hydration to promote diuresis and mitigate crystalluria risk. Both Puribel and its active metabolite, oxipurinol, are known to be dialyzable. Patients with impaired renal function carry an increased risk of severe toxicity due to the retention and accumulation of the oxipurinol metabolite.

Therapeutic Uses of Puribel

Main Uses and Therapeutic Areas

Puribel is a pharmacological treatment primarily indicated for the management of specific gastrointestinal and biliary conditions. Its main application involves the relief of symptoms associated with functional bowel disorders and the supportive treatment of chronic conditions affecting the gallbladder and bile ducts.

Gastrointestinal Motility and Spasms

The primary therapeutic function of Puribel is the management of abdominal pain and discomfort related to functional disturbances of the digestive tract. It is frequently utilized in cases of:

  • Irritable Bowel Syndrome (IBS): Assisting in the management of alternating bowel habits and abdominal cramping.
  • Functional Dyspepsia: Addressing discomfort located in the upper gastrointestinal region.
  • Biliary Colic: Providing relief for pain resulting from the movement or obstruction of gallstones within the bile ducts.

Biliary System Disorders

Puribel is also indicated for patients suffering from disorders of the biliary tree. By acting on the smooth muscles of the bile ducts, the medication helps facilitate the flow of bile, which can be beneficial in managing:

  • Chronic Cholecystitis: Long-term inflammation of the gallbladder.
  • Cholangitis: Inflammation of the bile duct system.
  • Post-cholecystectomy Syndrome: Symptoms that persist or develop following the surgical removal of the gallbladder.

Expected Benefits

The integration of Puribel into a treatment plan aims to achieve several clinical outcomes focused on patient comfort and physiological stabilization.

Symptom Relief

The most immediate benefit is the reduction of visceral hypersensitivity and smooth muscle spasms. Patients typically experience a decrease in the intensity and frequency of abdominal cramps, bloating, and the sensation of pressure in the digestive tract.

Improved Digestive Function

By normalizing the transit time of food and waste through the intestines, Puribel helps stabilize bowel movements. This stabilization can lead to a reduction in both urgency and the discomfort associated with irregular gastrointestinal motility.

Support for Biliary Drainage

In biliary applications, the medication assists in maintaining the patency of the bile ducts. Improved bile flow can prevent the accumulation of bile (cholestasis), thereby reducing the risk of further inflammation and associated digestive complications such as fat malabsorption or nausea.

Regulatory References

  1. European Medicines Agency Summary of Product Characteristics (SmPC)

Eligibility and Restrictions for Use

Who can and cannot use Puribel? — Official Regulatory Information

The eligibility for Puribel (Allopurinol) is strictly defined by regulatory authorities based on patient history, physiological status, and age.

Eligibility Classification Official Status Population/Condition
Contraindicated Absolute Prohibition Known Hypersensitivity to Allopurinol or a history of Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).
Not Recommended Conditional Prohibition Pregnancy and Lactation (due to excretion into breast milk).
Restricted Use Dose Adjustment Required Patients with impaired renal function or hepatic impairment.

Age-Related Eligibility

  • Adults are the primary approved age group for conditions like chronic gout and hyperuricemia.
  • Older Adults are permitted to use the medicine, but caution is advised, and doses may need adjustment due to the likelihood of reduced kidney function.
  • Pediatric Use is not recommended for standard adult indications. Use in children and adolescents is limited only to specific, severe conditions, such as secondary hyperuricemia related to malignancy or certain hereditary enzyme deficiencies.

Additional Restrictions

Puribel is generally not recommended for treating asymptomatic hyperuricemia alone. Individuals with certain genetic markers, such as the *HLA-B58:01 allele**, particularly those of Han Chinese, Thai, or Korean descent, are at a significantly higher risk of severe reactions, and use is restricted or prohibited in this group.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated and Restricted Combinations

Official regulatory information classifies the combination of Puribel with Pegloticase as contraindicated, specifically mandating that Puribel therapy must be discontinued and not initiated during the course of Pegloticase treatment. Co-administration with Capecitabine should also be avoided, as officially stated.

Exposure-Modifying Interactions

The most significant interaction involves a pharmacokinetic effect on agents metabolized by the Xanthine Oxidase enzyme. Puribel's inhibitory action on this enzyme leads to a substantial increase in the plasma exposure of both Mercaptopurine and Azathioprine. Regulatory documentation requires that the dose of these co-administered drugs be reduced to approximately one-third to one-fourth of the usual dose.

Other medicines known to experience an increase in concentration or effect include Vidarabine, Theophylline (at high Puribel doses), and Warfarin, necessitating close monitoring.

Heightened Risk and Pharmacodynamic Effects

Co-administration with several medicinal products is associated with an increased risk of hypersensitivity reactions or skin rash, which include Thiazide Diuretics, ACE Inhibitors, and certain antibiotics such as Ampicillin and Amoxicillin. This risk is specifically noted to be higher for patients with decreased renal function receiving concurrent thiazides. An interaction with Aluminum Hydroxide (antacids) requires a 3-hour separation in administration time. No known interactions with food or drinks are documented in official prescribing information.

Mechanism of Action

The mechanism of Puribel is defined by its selective Xanthine Oxidase Inhibition (XOI), a specific action within the purine catabolism pathway. The active substance, Allopurinol, is metabolized to its primary inhibitory compound, Oxypurinol.

Oxypurinol engages the Xanthine Oxidase (XO) enzyme by forming a highly stable, functionally inert complex with its catalytic site. This binding prevents the enzyme from performing the necessary oxidation steps required to convert precursor purines (Hypoxanthine and Xanthine) into Uric Acid.

The resulting molecular cascade causes a proportional decrease in the systemic rate of Uric Acid production, leading to a quantitative shift in the total body urate pool. This modulation alters the body’s metabolic flow and results in a sustained reduction in circulating Uric Acid concentration, which promotes a corresponding shift below the saturation threshold of urate in the physical-chemical environment of tissues.

Dosage and Administration Information

The following is a summary of the administration guidelines for Puribel (febuxostat) and is not clinical advice.

Official Administration and Dosing

Instruction Category Guideline
Route of Administration Oral (by mouth).
Standard Dosing Schedule The recommended starting dose is 40 mg once daily. After two weeks, if the target serum uric acid (sUA) level of <6 mg/dL is not achieved, the dose is increased to 80 mg once daily.
Maximum Daily Dose The maximum dose is 80 mg once daily. In certain management protocols, the maximum dose for chronic use is 120 mg once daily.
Timing in Relation to Food The tablet may be taken without regard to food or antacid use.

Special Procedural Conditions

  1. Dose Adjustment for Severe Renal Impairment: For patients with severe renal impairment, the dose must be limited to 40 mg once daily.
  2. Prophylaxis Requirement: Upon treatment initiation, concurrent prophylactic therapy (using a separate medication, such as an NSAID or colchicine) is recommended and may be beneficial for up to six months.
  3. Action During Flares: If a gout flare occurs while taking this medication, the treatment should not be discontinued; the flare must be managed concurrently.
  4. Missed Dose: If a dose is missed, take it as soon as possible, unless it is almost time for the next scheduled dose. If so, skip the missed dose and resume the regular schedule. Do not double the dose.

These instructions define the standardized, two-phase initial use protocol, requiring two weeks to assess the therapeutic response before any dose escalation is applied, while also mandating temporary co-treatment and prescribing specific limits for certain patient populations.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Puribel

Puribel (Allopurinol) has been studied over many decades, leading to an extensive body of research that supports its authorized uses. This overview summarizes the structure reported by major regulatory and scientific sources, describing the types of studies conducted and what was observed in patient groups.


Evidence for Use in Chronic Conditions

The core evidence for gout and high uric acid levels comes primarily from numerous Randomized Controlled Trials (RCTs) and Systematic Reviews. Researchers explored two key outcomes: changes measured in the Serum Uric Acid (SUA) level, which is a key physiological biomarker, and the frequency of acute gout attacks. Studies consistently monitored measurements showing changes in SUA levels across observed populations. Research also highlights data showing patterns related to the frequency of reported gout flares over time, with comparisons made against control groups. The evolution of tophi was also monitored, with studies reporting how their size evolved during the period of observation.


Evidence for Acute Conditions and Special Groups

Puribel was studied for use in patients facing a rapid, severe increase in uric acid levels (Tumor Lysis Syndrome). The evidence is often derived from supportive clinical studies in both adult and pediatric patients with malignancies. Research focused on the prevention of extreme spikes in the SUA level and observation of how the treatment was associated with markers of acute complications, such as Acute Kidney Injury (AKI). Furthermore, research examined how SUA levels evolved during long-term observation periods for chronic use, including in patient subgroups with Impaired Kidney Function.


Research Gaps and Uncertainty

Long-term effects are not fully established regarding outcomes beyond five years, and information regarding outcomes from decades of treatment is often drawn from observational studies rather than dedicated long-term RCTs. Subgroup findings are uncertain or limited for groups, such as those with advanced kidney failure. Comparative evidence against some newer therapies is lacking. Research primarily measures biomarkers (like SUA) and event frequency, providing limited insight into certain patient-reported outcomes describing perceived discomfort. The evidence highlights what is known—and what is still uncertain.

Key Studies & References

  1. 2020 American College of Rheumatology Guideline for the Management of Gout

Frequently Asked Questions (FAQ)

Common questions about Puribel (FAQ)

Q: What is the main reason doctors prescribe Puribel?

Puribel is approved by regulatory bodies to lower high levels of uric acid in the blood. This is primarily done to manage chronic gout, prevent tumor lysis syndrome (a rapid increase in uric acid due to cancer treatment), and prevent recurrent calcium kidney stones.

Q: Is Puribel a steroid or a type of hormone treatment?

No, Puribel is a synthetic compound known as a purine analog. It belongs to a pharmacological class called Xanthine Oxidase Inhibitors (XOI). This classification means it works by blocking a specific enzyme in the body to stop the production of uric acid, and it is not a steroid or hormone treatment.

Q: How is Puribel different from other medicines that treat the same condition?

Puribel is classified as a Xanthine Oxidase Inhibitor (XOI). Its mechanism is to directly reduce the body’s overall production of uric acid. This action differentiates it from medications used only to manage the acute pain and inflammation of a gout flare, such as pain relievers.

Q: Can Puribel be used for conditions other than what is on the label?

The medication is approved for specific, authorized conditions as defined in official documents. Regulatory information states that Puribel is not recommended for treating asymptomatic hyperuricemia (high uric acid without symptoms of gout). Decisions regarding use for any other condition are based on the medication's authorized indications.

Q: Do I need to change my diet while taking Puribel?

Official information states there are no known interactions with food or drinks. The medication should be used alongside any specific diet plan that may be recommended. This may include drinking sufficient amounts of non-caffeine liquids to help flush out uric acid.

Q: Is Puribel known to cause weight gain or weight loss?

Changes in body weight are not listed as common side effects in the medication’s profile. Unexplained weight loss or gain, however, may be a rare symptom associated with serious hepatic (liver) or renal (kidney) adverse events. Such events are noted in the safety profile as adverse events that warrant attention.

Q: How long does it usually take to feel the effects of Puribel?

While the drug begins lowering uric acid levels relatively quickly, it may take several months or longer before the full benefit is felt in terms of reduced gout flares. It is common for the frequency of gout attacks to temporarily increase during the first few months of starting treatment.

Q: Are the common side effects of Puribel serious?

Official documents categorize side effects into common and serious adverse reactions. Common effects, such as a mild rash or nausea, are distinct from serious reactions. Serious reactions, including severe skin rashes or signs of liver injury, are defined as clinically significant adverse events noted in the labeling.

Q: Can Puribel cause problems with sleep or insomnia?

Insomnia (difficulty sleeping) is not listed as a frequent side effect. However, rare adverse effects, such as agitation, nervousness, or anxiety, have been reported in the clinical profile and may potentially disrupt sleep patterns.

Q: Is it normal to feel a little dizzy when first starting Puribel?

Dizziness is reported in official documents as a known side effect of Puribel. This effect is associated with the medication's potential to cause drowsiness.

Q: What kind of monitoring or tests are needed while on Puribel?

Patient monitoring typically involves regular measurement of serum uric acid levels as a marker of treatment progress. Additionally, periodic complete blood counts, and liver and renal function tests are often conducted to monitor for any laboratory abnormalities reported in the adverse event profile.

Q: Does Puribel interact with common pain relievers like ibuprofen?

Official drug information indicates that Puribel can generally be taken with common non-steroidal anti-inflammatory drugs ( NSAIDs) like ibuprofen. The label notes that caution may be necessary when combining these medications in patients who have certain risk factors, such as existing kidney problems.

Q: Can I take Puribel if I also take supplements like vitamins or herbal remedies?

The safety and effectiveness of taking Puribel with complementary medicines, herbal remedies, and other supplements have not been fully established through mandatory regulatory studies. Regulatory compliance emphasizes the importance of sharing a complete list of all supplements with the prescribing physician.

Q: Does taking Puribel affect fertility in men or women?

Official warnings state that patients who intend to become pregnant or are planning a family should review the use of Puribel with their doctor. This discussion covers the necessary safety considerations related to reproductive health.

Q: What happens if I stop taking Puribel suddenly?

If treatment is stopped suddenly, official information warns that there is a high risk that gout symptoms may get worse. If discontinuation is necessary, it is important that this process be managed by a healthcare professional.

Q: Is Puribel addictive or habit-forming?

No. Regulatory information explicitly states that there is no evidence that the medication is addictive or habit-forming.

Q: Can Puribel cause mood changes or affect mental health?

While not listed as common, rare adverse effects in the clinical profile include anxiety, agitation, depression, and confusion. The adverse event profile lists rare psychiatric events, and any unexpected changes in behavior or mood are considered clinically relevant.

Q: Does Puribel affect the results of any common lab tests?

Yes, regulatory information notes that the medication may affect lab tests by causing specific abnormalities. These can include changes in liver enzymes (transaminitis), elevated alkaline phosphatase, and decreases in white blood cells (leukopenia) or platelets (thrombocytopenia).

Q: How long after stopping Puribel does it stay in my system?

The active substance in Puribel is metabolized into an active compound called oxypurinol, which has a half-life of approximately 15 hours. Due to this, it takes several days for the drug and its active form to be completely cleared from the body.

Q: What is the difference between the brand name and the generic version of Puribel?

Brand name and generic formulations contain the same active ingredient, allopurinol. Regulators require generic versions to be bioequivalent, meaning they work in the body in the same way to lower uric acid levels and are used for the same clinical purposes.

Q: Can Puribel make you more sensitive to the sun?

Photosensitivity (increased sensitivity to the sun) is not listed as a common side effect. However, the known risk of severe skin reactions is a serious safety concern, which may be triggered or exacerbated by excessive sun exposure.

Q: Are there any known interactions between Puribel and birth control pills?

Official drug interaction databases for the active ingredient do not list any known drug-specific interaction with common hormonal birth control pills.

Q: Can Puribel make you tired or drowsy?

Yes, official safety information indicates that this medication can cause drowsiness. Due to the potential for drowsiness, the prescribing information advises caution regarding activities that require full mental alertness.

Q: Is it normal to experience stomach upset when starting Puribel?

Stomach upset, including symptoms like nausea and diarrhea, is reported in clinical trials as a common side effect. The medication is sometimes administered after a meal or snack, which is a method reported to help reduce gastrointestinal effects.

Q: Does Puribel affect blood pressure or heart rate?

Clinical studies have investigated the medication's effect on the cardiovascular system. While a severe cardiovascular risk is noted in the labeling of one related drug, some research has suggested that Puribel may be associated with a reduced cardiovascular risk in certain high-risk patients with hyperuricemia.

Q: Can I split or crush Puribel tablets if I have trouble swallowing them?

Official information notes that Allopurinol tablets have been mixed with water or soft food for administration. Patients should be aware that crushing tablets for consumption is considered an unlicensed method of use.

Q: What are the restrictions on driving or operating machinery while taking Puribel?

Because Puribel can cause drowsiness or dizziness, the prescribing information includes warnings against driving a car or operating heavy machinery. This precaution is advised until the patient is aware of how the medication affects their level of alertness and coordination.

Q: Do the official documents mention any effects of Puribel on vision?

While severe vision loss is rare, the adverse event profile includes reports of symptoms such as blurred vision or irritation of the eyes. Any persistent visual changes, such as blurred vision or irritation of the eyes, are considered clinically relevant and should be noted.

Q: Are there any long-term safety concerns with taking Puribel for several years?

The long-term safety of chronic use, especially beyond five years, is continually investigated through post-market data and observational studies. Sustained monitoring for adverse events and laboratory abnormalities remains the standard practice for all patients on long-term therapy.

Q: Do I have to take Puribel at a specific time of day?

Puribel is typically prescribed as a once-daily dose and can be taken at any time of the day. While the dose can be taken at any time of the day, administration at a consistent time is a common strategy employed to promote treatment adherence.

Q: Can Puribel be taken with antacids or heartburn medication?

Puribel can generally be taken without regard to most antacids. However, official information notes that a 3-hour separation is recommended or required when the medication is administered alongside antacids containing aluminum hydroxide.

Q: What are the signs of an allergic reaction to Puribel?

Signs of a hypersensitivity or allergic reaction can include common symptoms like rash, hives, or itching. More serious signs noted in the labeling include fever, blistering or peeling skin, eye irritation, and swelling of the mouth, face, or throat, which are defined as clinically significant adverse events.

Q: What is the success rate of Puribel reported in clinical trials?

The clinical trial benchmark for success is measured by the percentage of patients who achieve a pre-defined therapeutic target. For the management of gout, this target is often a serum uric acid level below 6 mg/dL.

How should Puribel be stored and disposed of?

How to Store and Dispose of Puribel

Puribel (Allopurinol tablets) must be stored and handled according to specific official instructions to maintain product integrity and ensure safety.


Storage Conditions

Store the tablets in a dry environment at a temperature below 30°C (86°F), as required by regulatory labeling. It is mandatory to keep the medication in its original container and, if supplied in a bottle, the cap must be kept tightly closed to protect it from moisture. Do not refrigerate or freeze Puribel. All tablets must be kept out of the sight and reach of children and pets at all times.


Disposal Instructions

Unused or expired Puribel tablets must be disposed of according to local regulations. Do not discard the medicine via household trash or flush it down the toilet or sink, as this poses an environmental risk. The standard official instruction is to return the unwanted product to a pharmacy or an authorized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Puribel found in:

A-Z Index: